Eupraxia's EP-104GI Shows Durable EoE Remission in Phase 1b/2a Trial…

Event summary

Eupraxia's highest dose cohort (Cohort 9) of EP-104GI maintained 66% clinical remission at 52 weeks.
Cohort 8b showed histologic improvements with EoEHSS Stage –0.26 and Grade –0.27 at 36 weeks.
64% of patients (9/14) across Cohorts 5-9 remained in clinical remission at 52 weeks.
No treatment-related serious adverse events or corticosteroid-related side effects observed.
Phase 2b portion of the RESOLVE trial is recruiting, with interim data expected in December 2026.

The big picture

Eupraxia's Phase 1b/2a trial results for EP-104GI highlight the potential of its Diffusphere technology to deliver sustained therapeutic effects for EoE with a single annual dose. The data suggest a significant advancement in treating a disease with rapidly increasing prevalence, positioning Eupraxia as a key player in the inflammatory gastrointestinal space. The upcoming Phase 2b trial will be critical in validating these findings and determining the drug's commercial viability.

What we're watching

Clinical Efficacy: Whether the durable 52-week remission rates in Cohort 9 can be replicated in the Phase 2b trial.
Regulatory Pathway: The pace at which Eupraxia can advance EP-104GI toward approval given the positive Phase 1b/2a data.
Market Potential: How the annual dosing regimen aligns with ACG Guidelines and its potential impact on EoE treatment standards.